Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrevus in primary progressive multiple sclerosis
NCT04035005Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2019
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of ocrelizumab in primary progressive multiple sclerosis (PPMS), sponsored by Roche. Started Aug 2019; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT04035005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04035005.